Identificering af nye ovariecancerbiomarkører med massespektrometriske proteomanalyser--fremtidens diagnostiske redskab?

Anette Lykke Petri, Estrid Høgdall, Svend Aage Engelholm, Ib Jarle Christensen, Susanne Krüger Kjaer, Claus K Høgdall

Abstract

New non-invasive diagnostic tests for detection of ovarian cancer in early stages can improve survival. One approach is the proteomic analysis of serum or urine, which may be the technology needed. Preliminary proteomic analyses of serum and urine have shown a higher positive predictive value than that of the combination of serum CA125 and ultrasound examination, which actually is used preoperatively for the ovarian cancer diagnosis (RMI index). Identification of new ovarian cancer biomarkers will optimally be usable as an ovarian cancer-screening tool.

Bidragets oversatte titelIdentification of new ovarian cancer biomarkers with proteomic analyses--the diagnostic tool of the future?
OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind169
Udgave nummer33
Sider (fra-til)2614-9
Antal sider6
ISSN0041-5782
StatusUdgivet - 13 aug. 2007
Udgivet eksterntJa

Emneord

  • Biomarkers, Tumor/analysis
  • Female
  • Humans
  • Mass Screening/trends
  • Ovarian Neoplasms/diagnosis
  • Predictive Value of Tests
  • Proteomics/methods
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods

Fingeraftryk

Dyk ned i forskningsemnerne om 'Identificering af nye ovariecancerbiomarkører med massespektrometriske proteomanalyser--fremtidens diagnostiske redskab?'. Sammen danner de et unikt fingeraftryk.

Citationsformater